Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
C J Cates
Dr C J Cates, St George’s, University of London, London, UK; email@example.com
In patients with chronic asthma, does daily salmeterol increase serious adverse events (SAEs) and mortality more than placebo or short-acting β-agonists?
Included studies compared salmeterol alone, given twice daily for ⩾12 weeks using an inhaler, with placebo or short-acting β-agonists in patients with chronic asthma. Outcomes included all-cause mortality, non-fatal SAEs, and asthma mortality.
Cochrane Airways Group Specialised Register (Oct 2007), websites of clinical trial registers and drug manufacturers, US Food and Drug Administration submissions, and reference lists were searched for published and unpublished data from randomised controlled trials …
Source of funding: National Institute for Health Research.